

# Michael T Spiotto

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9328566/publications.pdf>

Version: 2024-02-01

66  
papers

3,104  
citations

304743

22  
h-index

182427

51  
g-index

68  
all docs

68  
docs citations

68  
times ranked

4745  
citing authors

#	ARTICLE	IF	CITATIONS
1	Proton Image-guided Radiation Assignment for Therapeutic Escalation via Selection of locally advanced head and neck cancer patients [PIRATES]: A Phase I safety and feasibility trial of MRI-guided adaptive particle radiotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2022, 32, 35-40.	1.7	3
2	Genetic Changes Driving Immunosuppressive Microenvironments in Oral Premalignancy. <i>Frontiers in Immunology</i> , 2022, 13, 840923.	4.8	13
3	Synergistic checkpoint-blockade and radiotherapyâ€“radiodynamic therapy via an immunomodulatory nanoscale metalâ€“organic framework. <i>Nature Biomedical Engineering</i> , 2022, 6, 144-156.	22.5	47
4	Decreased overall survival in patients with locally advanced head and neck cancer receiving definitive radiotherapy and concurrent cetuximab: National Cancer Database analysis. <i>Head and Neck</i> , 2022, , .	2.0	3
5	Patterns of Care and Survival Outcomes for Odontogenic Cancers. <i>Laryngoscope</i> , 2021, 131, E1496-E1502.	2.0	1
6	Impact of anatomic site of distant metastasis on survival in salivary gland cancers. <i>Head and Neck</i> , 2021, 43, 2589-2601.	2.0	2
7	Proton Radiotherapy to Reduce Late Complications in Childhood Head and Neck Cancers. <i>International Journal of Particle Therapy</i> , 2021, 8, 155-167.	1.8	4
8	Proton Therapy for HPV-Associated Oropharyngeal Cancers of the Head and Neck: a De-Intensification Strategy. <i>Current Treatment Options in Oncology</i> , 2021, 22, 54.	3.0	11
9	Stereotactic body ablative radiotherapy for reirradiation of small volume head and neck cancers is associated with prolonged survival: Large, singleâ€“institution, modern cohort study. <i>Head and Neck</i> , 2021, 43, 3331-3344.	2.0	15
10	Biology of the Radio- and Chemo-Responsiveness in HPV Malignancies. <i>Seminars in Radiation Oncology</i> , 2021, 31, 274-285.	2.2	13
11	Notch Signaling and Human Papillomavirusâ€“Associated Oral Tumorigenesis. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1287, 105-122.	1.6	5
12	Reprogramming of Neutrophils as Non-canonical Antigen Presenting Cells by Radiotherapyâ€“Radiodynamic Therapy to Facilitate Immune-Mediated Tumor Regression. <i>ACS Nano</i> , 2021, 15, 17515-17527.	14.6	22
13	Increased Disparities in Patients Diagnosed with Metastatic Lung Cancer Following Lung CT Screening in the United States. <i>Clinical Lung Cancer</i> , 2021, , .	2.6	4
14	The Risk Is Worth the Reward: Regional-Only Recurrence Is Curable with Nodal Dissection. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 239-240.	0.8	0
15	Prostate Cancer Radiotherapy: Increased Biochemical Control and Late Toxicity in Men With Medication Allergies. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa081.	2.9	0
16	A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 487-498.	0.8	29
17	Cooperation of genes in HPV16 <i>E6/E7</i>-dependent cervicovaginal carcinogenesis trackable by endoscopy and independent of exogenous estrogens or carcinogens. <i>Carcinogenesis</i> , 2020, 41, 1605-1615.	2.8	8
18	Machine Learningâ€“Guided Adjuvant Treatment of Head and Neck Cancer. <i>JAMA Network Open</i> , 2020, 3, e2025881.	5.9	65

#	ARTICLE	IF	CITATIONS
19	Machine learning guided adjuvant treatment of head and neck cancer.. Journal of Clinical Oncology, 2020, 38, 6567-6567.	1.6	1
20	Mevalonate pathway activity as a determinant of radiation sensitivity in head and neck cancer. Molecular Oncology, 2019, 13, 1927-1943.	4.6	17
21	Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall: A National Cancer Database Analysis. Lung Cancer, 2019, 130, 162-168.	2.0	16
22	Patterns of Care and Outcomes of Intensity-Modulated Radiotherapy and 3D Conformal Radiotherapy for Early Stage Glottic Cancer: A National Cancer Database Analysis. Cancers, 2019, 11, 1996.	3.7	13
23	Molecular Classification of Lymph Node Metastases Subtypes Predict for Survival in Head and Neck Cancer. Clinical Cancer Research, 2019, 25, 1795-1808.	7.0	24
24	Low-dose X-ray radiotherapyâ€“radiodynamic therapy via nanoscale metalâ€“organic frameworks enhances checkpoint blockade immunotherapy. Nature Biomedical Engineering, 2018, 2, 600-610.	22.5	438
25	Differences in Survival With Surgery and Postoperative Radiotherapy Compared With Definitive Chemoradiotherapy for Oral Cavity Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 691.	2.2	54
26	Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy. Lung Cancer, 2017, 108, 222-227.	2.0	22
27	Impact of fraction size on locally advanced oropharyngeal and nasopharyngeal cancers treated with chemoradiation. Oral Oncology, 2017, 68, 27-35.	1.5	3
28	Survival outcomes for postoperative chemoradiation in intermediateâ€“risk oral tongue cancers. Head and Neck, 2017, 39, 2537-2548.	2.0	8
29	Association between hospital volume and receipt of treatment and survival in patients with glioblastoma. Journal of Neuro-Oncology, 2017, 135, 529-534.	2.9	20
30	A High-Throughput Cell-Based Screen Identified a 2-[(E)-2-Phenylvinyl]-8-Quinololinol Core Structure That Activates p53. PLoS ONE, 2016, 11, e0154125.	2.5	4
31	Predictors and outcomes for chronic tracheostomy after chemoradiation for advanced laryngohypopharyngeal cancer. Laryngoscope, 2016, 126, 385-391.	2.0	16
32	Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer. Journal of Otolaryngology - Head and Neck Surgery, 2016, 45, 62.	1.9	16
33	Return of induction chemotherapy in head and neck squamous cell cancers: is this time different?. Lancet Oncology, The, 2016, 17, 1465-1467.	10.7	1
34	The intersection of radiotherapy and immunotherapy: Mechanisms and clinical implications. Science Immunology, 2016, 1, .	11.9	149
35	Strategies to Overcome Late Complications from Radiotherapy for Childhood Head and Neck Cancers. Oral and Maxillofacial Surgery Clinics of North America, 2016, 28, 115-126.	1.0	3
36	Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance. Oncotarget, 2016, 7, 43039-43051.	1.8	62

#	ARTICLE	IF	CITATIONS
37	Angiotensin-converting enzyme inhibitors predict acute kidney injury during chemoradiation for head and neck cancer. <i>Anti-Cancer Drugs</i> , 2015, 26, 343-349.	1.4	8
38	Notch1 Activation or Loss Promotes HPV-Induced Oral Tumorigenesis. <i>Cancer Research</i> , 2015, 75, 3958-3969.	0.9	25
39	Hospitalizations of more than 5 days predict for worse outcomes after radiotherapy for head and neck cancer. <i>Journal of Community and Supportive Oncology</i> , 2015, 13, 367-373.	0.1	2
40	Loss of E2F1 Extends Survival and Accelerates Oral Tumor Growth in HPV-Positive Mice. <i>Cancers</i> , 2015, 7, 2372-2385.	3.7	8
41	Racial parities in outcomes after radiotherapy for head and neck cancer. <i>Cancer</i> , 2014, 120, 244-252.	4.1	24
42	Race and competing mortality in advanced head and neck cancer. <i>Oral Oncology</i> , 2014, 50, 40-44.	1.5	27
43	Comparison of carboplatin+paclitaxel to docetaxel+cisplatin+5-fluorouracil induction chemotherapy followed by concurrent chemoradiation for locally advanced head and neck cancer. <i>Oral Oncology</i> , 2014, 50, 52-58.	1.5	18
44	Bioluminescent Imaging of HPV-Positive Oral Tumor Growth and Its Response to Image-Guided Radiotherapy. <i>Cancer Research</i> , 2014, 74, 2073-2081.	0.9	23
45	The Effect of Radiotherapy Dose on Survival in Stage III Non-Small-Cell Lung Cancer Patients Undergoing Definitive Chemoradiotherapy. <i>Clinical Lung Cancer</i> , 2014, 15, 365-371.	2.6	9
46	Effect of Postradiotherapy Neck Dissection on Nonregional Disease Sites. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2014, 140, 12.	2.2	2
47	Comparison of 3D Conformal Radiotherapy and Intensity Modulated Radiotherapy with or without Simultaneous Integrated Boost during Concurrent Chemoradiation for Locally Advanced Head and Neck Cancers. <i>PLoS ONE</i> , 2014, 9, e94456.	2.5	44
48	Animal Models to Study the Mutational Landscape for Oral Cavity and Oropharyngeal Cancers. <i>Journal of Oral &amp; Maxillofacial Research</i> , 2013, 4, e1.	1.0	20
49	Spleen Cells from Young but Not Old Immunized Mice Eradicate Large Established Cancers. <i>Clinical Cancer Research</i> , 2012, 18, 2526-2533.	7.0	22
50	Imaging the Unfolded Protein Response in Primary Tumors Reveals Microenvironments with Metabolic Variations that Predict Tumor Growth. <i>Cancer Research</i> , 2010, 70, 78-88.	0.9	90
51	Stereotactic body radiotherapy for primary and oligometastatic cancers. <i>Community Oncology</i> , 2009, 6, 456-462.	0.2	1
52	Preferential Cytotoxicity of Bortezomib toward Hypoxic Tumor Cells via Overactivation of Endoplasmic Reticulum Stress Pathways. <i>Cancer Research</i> , 2008, 68, 9323-9330.	0.9	126
53	Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. <i>Journal of Experimental Medicine</i> , 2007, 204, 49-55.	8.5	348
54	Floxed reporter genes: Flow-cytometric selection of clonable cells expressing high levels of a target gene after tamoxifen-regulated Cre-loxP recombination. <i>Journal of Immunological Methods</i> , 2006, 312, 201-208.	1.4	3

#	ARTICLE	IF	CITATIONS
55	Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells. <i>Cancer Immunity</i> , 2005, 5, 8.	3.2	42
56	Bystander elimination of antigen loss variants in established tumors. <i>Nature Medicine</i> , 2004, 10, 294-298.	30.7	235
57	Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation. <i>Current Opinion in Immunology</i> , 2003, 15, 725-730.	5.5	48
58	Complementary Role of CD4+ T Cells and Secondary Lymphoid Tissues for Cross-presentation of Tumor Antigen to CD8+ T Cells. <i>Journal of Experimental Medicine</i> , 2003, 197, 985-995.	8.5	69
59	Genetic changes occurring in established tumors rapidly stimulate new antibody responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 5425-5430.	7.1	16
60	Increasing Tumor Antigen Expression Overcomes "Ignorance" to Solid Tumors via Crosspresentation by Bone Marrow-Derived Stromal Cells. <i>Immunity</i> , 2002, 17, 737-747.	14.3	216
61	Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines. , 2000, 42, 1-7.		86
62	STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP. <i>Prostate</i> , 2000, 42, 88-98.	2.3	122
63	STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. , 2000, 42, 186-195.		162
64	Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines Presented at the American Association for Cancer Research Special Conference "New Research Approaches in the Prevention and Cure of Prostate Cancer," December 2-6, 1998, Indian Wells, CA. <i>Prostate</i> , 2000, 42, 1.	2.3	3
65	Characterization of the role of IL-6 in the progression of prostate cancer. , 1999, 38, 199-207.		190
66	Characterization of the role of IL-6 in the progression of prostate cancer. <i>Prostate</i> , 1999, 38, 199-207.	2.3	2